In:
American Journal of Hematology, Wiley, Vol. 88, No. 7 ( 2013-07), p. 594-600
Abstract:
Acute myeloid leukemia (AML) with deranged core‐binding factor beta (CBFβ) is usually associated with a favorable prognosis with 50–70% of patients cured using contemporary treatments. We analyzed the prognostic significance of clinical features on 58 patients with CBFβ‐AML aged ≤60 years. Increasing age was the only predictor for survival ( P 〈 0.001), with an optimal cut‐point at 43 years. White blood cells (WBCs) at diagnosis emerged as an independent risk factor for relapse incidence ( P = 0.017), with 1.1% increase of hazard for each 1.0 × 10 9 /L WBC increment. KIT mutations lacked prognostic value for survival and showed only a trend for relapse incidence ( P = 0.069). Am. J. Hematol. 88:594–600, 2013. © 2013 Wiley Periodicals, Inc.
Type of Medium:
Online Resource
ISSN:
0361-8609
,
1096-8652
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
1492749-4
Bookmarklink